goserelin
information and resources from the National Cancer Institute
NCI Thesaurus | goserelin
A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.NCI Thesaurus | goserelin
A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.
|
|
|
|
news articles
Ambrilia Announces Fiscal 2005 Results and Appointment of Three ... Mar 22, 2006
Genetic Engineering News, The second product is a sustained-release formulation of Goserelin, used primarily in hormone-sensitive prostate cancer, and is expected to be launched in ...
New Data Show Zometa Increased Bone Mineral Density in Breast ... Mar 22, 2006
PharmaLive.com (press release), ...inhibitor associated bone loss in premenopausal women with hormone-responsive breast cancer receiving combination endocrine treatment (goserelin and tamoxifen ...
Procyon Announces the Completion of the Acquisition of Cellpep SA ... Mar 1, 2006
PharmaLive.com (press release), The second product, Goserelin, is expected to be launched in Europe in 2008. With these late-stage products, Ambrilia Biopharma ...
Procyon Shareholders Approve Cellpep Acquisition Feb 27, 2006
International News Service, ...in the US in 2008. The second product, Goserelin, is expected to be launched in Europe in 2008. "Today's vote confirmed the strong ...
Goserelin to remain available to NZers Dec 18, 2005
Scoop.co.nz (press release), People with prostate cancer and breast cancer will continue to have fully funded access to the hormonal treatment goserelin (Zoladex) following an agreement ...
Breast Cancer Treatment Dec 16, 2005
Food Consumer, Adjuvant Therapy in Pre- and Perimenopausal Women with Node-Negative Breast Cancer: Cyclophosphamide/Methotrexate/Fluorouracil (CMF) vs Goserelin vs Sequential ...
Cancer medicine to be withdrawn due to subsidy cut Dec 14, 2005
Scoop.co.nz (press release), Zoladex® is the brand name for goserelin, an hormonal agent for the treatment of both breast and prostate cancer, made by AstraZeneca. ...
New Data Show Survival Benefit for Arimidex(TM) in Early Breast ... Dec 9, 2005
news aktuell (Pressemitteilung), ...including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed ...
Prostate cancer: awaiting innovation Dec 8, 2005
Pharmaceutical Business Review ...hormone (LHRH) agonist monotherapy remains the most commonly used drug therapy for prostate cancer, and agents such as leuprolide and goserelin are considered ...
AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
PR Newswire (press release), ...powder), RHINOCORT AQUA(R) (budesonide), SEROQUEL(R) (quetiapine fumarate), TOPROL-XL(R) (metoprolol succinate), ZOLADEX(R) (goserelin acetate implant), ZOMIG(R ...
|
|
